Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Endocrinology

Protecting Your Long-Term Health and Your Family

At a Glance

Familial hyperaldosteronism type II requires lifelong monitoring of blood pressure, potassium, and kidney function to reduce heart, brain, and kidney complications. Because it can be inherited through a CLCN2 variant, first-degree relatives may benefit from genetic counseling and testing.

Managing Familial Hyperaldosteronism Type II (FH-II) is a lifelong commitment to protecting your “target organs”—your heart, brain, and kidneys [1]. Because aldosterone excess does more than just raise your blood pressure, it can cause “silent” damage even when you feel fine [2]. Long-term success is measured by how well your treatment prevents these risks while closely monitoring your body’s response to medication [3][4].

Long-Term Health Risks

Compared to people with ordinary high blood pressure, those with untreated Primary Aldosteronism (PA) face significantly higher risks of serious health events [5]. This is because aldosterone causes physical changes to the heart and blood vessels that go beyond just the “pressure” in the system [6].

  • Atrial Fibrillation (AFib): Population-level studies estimate that patients with PA have a roughly 3.5 times higher risk of developing an irregular heart rhythm than those with essential hypertension [5].
  • Heart Failure and Stroke: Observational estimates suggest the risk of stroke is roughly 2.5 times higher, and the risk of heart failure is double that of standard hypertension patients [5][6].
  • Left-Ventricular Hypertrophy: Excess aldosterone causes the walls of the heart to thicken, which can make the heart less efficient over time [5].

Note: These risk figures are broad population estimates, not individual predictions. Effective medical treatment significantly reduces these risks, but general cardiovascular protection—like lipid management and smoking cessation—remains vital.

The “Renal Unmasking” Phenomenon

When you start taking Mineralocorticoid Receptor Antagonists (MRAs) like spironolactone or eplerenone, you may notice your creatinine levels rise or your eGFR (estimated Glomerular Filtration Rate) drop [7][8].

While this looks like “kidney damage” on a lab report, it can be a sign of the reversal of hyperfiltration (also called renal unmasking) [9][10]. High aldosterone forces your kidneys to “hyperfiltrate”—meaning they work at an artificially fast, unsustainable speed that masks underlying kidney issues [7][4]. When treatment blocks the aldosterone, the kidneys return to their true baseline speed. This “dip” in function often stabilizes over time [8][11].

However, do not assume a rising creatinine is benign. True acute kidney injury, severe volume depletion, or dangerous hyperkalemia are also possible. If the change is rapid, progressive, or accompanied by reduced urine output or severe weakness, you must contact your care team promptly.

Your Surveillance Schedule

Close monitoring is essential, particularly when starting an MRA or changing your dose, to ensure your potassium is safe and the medication is effective [12][13]. Your schedule will be individualized, but generally includes:

Phase of Treatment What is Checked Why it Matters
Soon After Initiation or Dose Changes Potassium & Creatinine To catch early spikes in potassium or significant kidney shifts shortly after starting or adjusting an MRA [7][14].
Titration Phase Potassium, BP, & Renin To safely adjust your dose; some specialists aim to titrate until renin is unsuppressed [4][12].
Long-Term Monitoring Individualized Labs & Clinical Exam Once stable, you will have routine checks of organ health. Tests like an ECG or echocardiogram are performed based on clinical judgment and symptoms [3][15][13].

Protecting Your Family: Cascade Testing

Because CLCN2-associated FH-II is an autosomal dominant condition, your first-degree relatives (parents, siblings, and children) may carry the same pathogenic CLCN2 variant [1][16].

Cascade testing is the process of using your genetic results to screen your family [17].

  • Who to Screen: All appropriate at-risk relatives should be offered targeted testing—even those who have normal blood pressure—because penetrance and age of onset can vary [18].
  • Understanding Risk: Each of your biological children has a 50% chance of carrying the variant. Sibling risk depends on whether a parent carries it. (If your variant is de novo, or new in you, sibling risk is generally much lower).
  • Testing Kids: Since FH-II can appear in childhood (sometimes as early as age 9), children of affected parents should be evaluated [19][20].
  • Genetic Counseling: It is highly recommended that relatives meet with a genetic counselor to discuss the implications of testing, privacy, and reproductive choices before proceeding [16].

Identifying the pathogenic CLCN2 variant early in a relative can prevent years of “silent” heart damage by allowing them to start targeted treatment long before a stroke or heart crisis occurs [21][5].

Common questions in this guide

How does FH-II affect long-term heart and stroke risk?
Excess aldosterone and high blood pressure can raise the risk of atrial fibrillation, heart failure, stroke, and thickening of the heart muscle. Treating aldosterone excess and managing other cardiovascular risks can lower these dangers, but population statistics cannot predict one person’s outcome.
Why did my creatinine change after I started spironolactone or eplerenone?
These medicines can reverse the kidney’s abnormally high filtering rate, causing a temporary creatinine rise or eGFR drop known as renal unmasking. A rapid or continuing change, reduced urine output, or severe weakness could signal kidney injury or high potassium, so contact your care team promptly.
When should my potassium and kidney function be checked during MRA treatment?
Potassium and creatinine are usually checked soon after a mineralocorticoid receptor antagonist, such as spironolactone or eplerenone, is started or its dose changes. During dose adjustment, clinicians may also follow blood pressure and renin; once treatment is stable, the schedule is individualized.
Should my relatives get tested for the CLCN2 variant?
First-degree relatives—parents, siblings, and children—should be offered targeted testing when a pathogenic CLCN2 variant causes FH-II, even if their blood pressure is normal. A genetic counselor can explain the possible results, privacy issues, and next steps.
What is the chance that my child will inherit FH-II?
Because CLCN2-associated FH-II is autosomal dominant, each biological child of a person who carries the variant has a 50% chance of inheriting it. The age when it appears and its effects can vary, so genetic counseling can help with testing and reproductive decisions.
What symptoms or test changes should prompt an urgent call to my care team?
Call promptly about a rapid or progressive creatinine rise, much less urine, or severe weakness after treatment changes. These findings can reflect acute kidney injury, dehydration, or dangerously high potassium rather than a harmless treatment-related change.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Familial hyperaldosteronism type II.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What was my baseline creatinine level before starting treatment, and what degree of change should prompt me to call you?
  2. 2.Is my current renin level an appropriate adjunctive target for me, given my kidney function and blood pressure?
  3. 3.Do we need to perform an echocardiogram to check for left-ventricular hypertrophy or other signs of heart strain?
  4. 4.Can you refer my family to a genetic counselor to discuss cascade testing for the CLCN2 variant?
  5. 5.What is my personalized follow-up schedule for blood tests when my dose is stable?

References

References (21)
  1. 1

    CLCN2 chloride channel mutations in familial hyperaldosteronism type II.

    Scholl UI, Stölting G, Schewe J, et al.

    Nature genetics 2018; (50(3)):349-354 doi:10.1038/s41588-018-0048-5.

    PMID: 29403011
  2. 2

    Normotensive hypokalemic primary hyperaldosteronism mimicking clinical features of anorexia nervosa in a young patient: A case report.

    Huang YC, Tsai MH, Fang YW, Tu ML

    Medicine 2020; (99(29)):e20826 doi:10.1097/MD.0000000000020826.

    PMID: 32702825
  3. 3

    Taiwan mini-frontier of primary aldosteronism: Updating treatment and comorbidities detection.

    Chan CK, Chang YY, Tsai YC, et al.

    Journal of the Formosan Medical Association = Taiwan yi zhi 2021; (120(10)):1811-1820 doi:10.1016/j.jfma.2021.03.032.

    PMID: 33906783
  4. 4

    Treatment of Primary Aldosteronism.

    Parisien-La Salle S, Hundemer GL, Nehs MA, et al.

    Hypertension (Dallas, Tex. : 1979) 2026; (83(5)):e26238 doi:10.1161/HYPERTENSIONAHA.126.26238.

    PMID: 41808633
  5. 5

    Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis.

    Monticone S, D'Ascenzo F, Moretti C, et al.

    The lancet. Diabetes & endocrinology 2018; (6(1)):41-50 doi:10.1016/S2213-8587(17)30319-4.

    PMID: 29129575
  6. 6

    Global and regional prevalence and cardiovascular risk of primary aldosteronism: a systematic review and meta-analysis.

    Huang M, Li J, Zhao X, et al.

    Current problems in cardiology 2024; (49(10)):102791 doi:10.1016/j.cpcardiol.2024.102791.

    PMID: 39127431
  7. 7

    Renal damage in primary aldosteronism: a systematic review and meta-analysis.

    Monticone S, Sconfienza E, D'Ascenzo F, et al.

    Journal of hypertension 2020; (38(1)):3-12 doi:10.1097/HJH.0000000000002216.

    PMID: 31385870
  8. 8

    Change in kidney function after unilateral adrenalectomy in patients with primary aldosteronism: identification of risk factors for decreased kidney function.

    Kim IY, Park IS, Kim MJ, et al.

    International urology and nephrology 2018; (50(10)):1887-1895 doi:10.1007/s11255-018-1887-9.

    PMID: 29779118
  9. 9

    Markers of Kidney Tubular Function Deteriorate While Those of Kidney Tubule Health Improve in Primary Aldosteronism After Targeted Treatments.

    Wu VC, Chan CK, Chueh JS, et al.

    Journal of the American Heart Association 2023; (12(4)):e028146 doi:10.1161/JAHA.122.028146.

    PMID: 36789834
  10. 10

    Outcomes of drug-based and surgical treatments for primary aldosteronism.

    Steichen O, Lorthioir A, Zinzindohoue F, et al.

    Advances in chronic kidney disease 2015; (22(3)):196-203.

    PMID: 25908468
  11. 11

    Long-term effects of primary aldosteronism treatment on patients with primary aldosteronism and chronic kidney disease.

    Nakano Y, Murakami M, Hara K, et al.

    Clinical endocrinology 2023; (98(3)):323-331 doi:10.1111/cen.14849.

    PMID: 36367014
  12. 12

    Increased Dosage of MRA Improves BP and Urinary Albumin Excretion in Primary Aldosteronism With Suppressed Plasma Renin.

    Saiki A, Otsuki M, Tamada D, et al.

    Journal of the Endocrine Society 2022; (6(1)):bvab174 doi:10.1210/jendso/bvab174.

    PMID: 34909517
  13. 13

    Primary Aldosteronism in a Hispanic Cohort: Responses to Mineralocorticoid Receptor Antagonism and Remission in a Case.

    Tapia-Castillo A, Vecchiola A, Quiñones P, et al.

    American journal of hypertension 2025; (38(6)):354-360 doi:10.1093/ajh/hpaf020.

    PMID: 39963937
  14. 14

    Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men's Issue?

    Manolis AA, Manolis TA, Melita H, Manolis AS

    Current hypertension reports 2019; (21(3)):22 doi:10.1007/s11906-019-0924-0.

    PMID: 30826898
  15. 15

    Mineralocorticoid Receptor Antagonists in Primary Aldosteronism.

    Stavropoulos K, Papadopoulos C, Koutsampasopoulos K, et al.

    Current pharmaceutical design 2018; (24(46)):5508-5516 doi:10.2174/1381612825666190311130138.

    PMID: 30854950
  16. 16

    SFE/SFHTA/AFCE consensus on primary aldosteronism, part 5: Genetic diagnosis of primary aldosteronism.

    Zennaro MC, Jeunemaitre X

    Annales d'endocrinologie 2016; (77(3)):214-9.

    PMID: 27315758
  17. 17

    Familial hyperaldosteronism: an European Reference Network on Rare Endocrine Conditions clinical practice guideline.

    Mulatero P, Scholl UI, Fardella CE, et al.

    European journal of endocrinology 2024; (190(4)):G1-G14 doi:10.1093/ejendo/lvae041.

    PMID: 38571460
  18. 18

    Primary aldosteronism diagnosis in the intensive care unit: resistant alkalosis and hypokalemia during severe sepsis with hyperlactatemia: a case report.

    Garg Y, Vaishnav MS, Harsha R, et al.

    Journal of medical case reports 2025; (19(1)):192 doi:10.1186/s13256-025-05112-6.

    PMID: 40281610
  19. 19

    A gain-of-function mutation in the CLCN2 chloride channel gene causes primary aldosteronism.

    Fernandes-Rosa FL, Daniil G, Orozco IJ, et al.

    Nature genetics 2018; (50(3)):355-361 doi:10.1038/s41588-018-0053-8.

    PMID: 29403012
  20. 20

    [Hyperaldosteronism].

    Scholl UI

    Der Internist 2021; (62(3)):245-251 doi:10.1007/s00108-021-00972-8.

    PMID: 33599784
  21. 21

    Aldosterone and Cardiovascular Risk Across the Lifespan.

    Ananda RA, Mori TA, Yang J

    Metabolites 2025; (15(8)) doi:10.3390/metabo15080553.

    PMID: 40863169

This page is for informational purposes only and does not constitute medical advice. Your clinician and genetic counselor can tailor FH-II monitoring, treatment, and family testing to your situation.